Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 15;384(15):1466-1468.
doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8.

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu  1 , Jianying Liu  1 , Hongjie Xia  1 , Xianwen Zhang  1 , Camila R Fontes-Garfias  1 , Kena A Swanson  2 , Hui Cai  2 , Ritu Sarkar  2 , Wei Chen  2 , Mark Cutler  2 , David Cooper  2 , Scott C Weaver  1 , Alexander Muik  3 , Ugur Sahin  3 , Kathrin U Jansen  2 , Xuping Xie  4 , Philip R Dormitzer  5 , Pei-Yong Shi  6
Affiliations

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Serum Neutralization of Variant Strains of SARS-CoV-2 after the Second Dose of BNT162b2 Vaccine.
Shown are the results of 50% plaque reduction neutralization testing (PRNT50) with the use of 20 samples obtained from 15 trial participants 2 weeks (circles) or 4 weeks (triangles) after the administration of the second dose of the BNT162b2 vaccine. The mutant viruses were obtained by engineering the full set of mutations in the B.1.1.7, P.1., or B.1.351 lineage or subsets of the S gene mutations in the B.1.351 lineage (B.1.351-Δ242-244+D614G and B.1.351-RBD+D614G) into USA-WA1/2020. Each data point represents the geometric mean PRNT50 obtained with a serum sample against the indicated virus, including data from repeat experiments, as detailed in Table S1 in the Supplementary Appendix. The data for USA-WA1/2020 are from three experiments; for B.1.1.7-spike, B.1.351-Δ242-244+D614G, and B.1.351-RBD-D614G viruses from one experiment each; and for P.1-spike and B.1.351-spike viruses from two experiments each. In each experiment, the neutralization titer was determined in duplicate assays, and the geometric mean was taken. The heights of bars and the numbers over the bars indicate geometric mean titers. The 𝙸 bars indicate 95% confidence intervals. Statistical analysis was performed with the use of the Wilcoxon signed-rank test. The statistical significance of the difference between geometric mean titers in the USA-WA1/2020 neutralization assay and in each variant virus neutralization assay with the same serum samples are as follows: P=0.02 for B.1.1.7-spike; P=0.06 for P.1-spike; P<0.001 for B.1.351-spike; P=0.99 for B.1.351-Δ242-244+D614G; and P=0.005 for B.1.351-RBD+D614G. LOD denotes limit of detection.
See this image and copyright information in PMC

Similar articles

  • Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. Wu K, et al. N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17. N Engl J Med. 2021. PMID: 33730471 Free PMC article. Clinical Trial. No abstract available.
  • Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
    Wang Y. Wang Y. EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3. EBioMedicine. 2021. PMID: 34742128 Free PMC article. No abstract available.
  • mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC. Wang Z, et al. Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10. Nature. 2021. PMID: 33567448 Free PMC article.
  • Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S. Pascolo S. Viruses. 2021 Feb 9;13(2):270. doi: 10.3390/v13020270. Viruses. 2021. PMID: 33572452 Free PMC article. Review.
  • The challenge of emerging SARS-CoV-2 mutants to vaccine development.
    Li R, Liu J, Zhang H. Li R, et al. J Genet Genomics. 2021 Feb 20;48(2):102-106. doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20. J Genet Genomics. 2021. PMID: 33994322 Free PMC article. Review. No abstract available.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed
    1. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439-2450. - PMC - PubMed
    1. Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020. (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. - DOI
    1. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020;26:842-844. - PubMed
    1. Skelly DT, Harding AC, Gilbert-Jaramillo J, et al. Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern. February 9, 2021. (https://www.researchsquare.com/article/rs-226857/v1). preprint.